Kiper Christopher S reported acquisition or exercise transactions in this Form 4 filing.
Lifecore Biomedical director Christopher S. Kiper reported an equity award linked to his board service. He received 25,907 restricted stock units (RSUs), each representing a contingent right to one share of Common Stock, at a stated price of $0.00 per unit. The RSUs vest on the earlier of June 4, 2027 or the first annual stockholder meeting held in 2027, if that meeting occurs at least 50 weeks after June 4, 2026. After this award, Kiper reports 103,482 shares/RSUs directly, while affiliated Legion funds report indirect holdings including 4,084,268 shares held by Legion Partners, L.P. I and 319,286 shares held by Legion Partners, L.P. II. Footnotes state that the economic interest in securities granted for Kiper’s board role belongs to Legion Partners Asset Management and its affiliates.
Lifecore Biomedical director Nelson Obus received an equity grant in the form of restricted stock units. The award covers 25,907 RSUs that convert into common stock on a 1-for-1 basis. These units vest on the earlier of June 4, 2027 or the company’s 2027 annual stockholder meeting, provided that date is at least 50 weeks after June 4, 2026. Following this grant, Obus holds 164,100 shares of Lifecore Biomedical common stock directly.
Lifecore Biomedical director Jason Aryeh received an equity award of 25,907 shares of common stock as a grant, not an open-market purchase. The award reflects restricted stock units that convert into common stock on a 1-for-1 basis. Following this grant, he directly holds 69,967 shares. The units vest on the earlier of June 4, 2027 or the date of the company’s 2027 annual meeting of stockholders, provided that meeting occurs at least 50 weeks after June 4, 2026.
Lifecore Biomedical director Joshua Schechter received an equity grant as part of his compensation. On the reported date, he was awarded 25,907 restricted stock units that convert into common stock on a 1-for-1 basis at no cash cost to him.
The grant vests on the earlier of June 4, 2027 or the date of the company’s annual meeting of stockholders first held in calendar year 2027, provided that meeting occurs at least 50 weeks after June 4, 2026. After this award, Schechter directly holds 133,080 shares of Lifecore common stock.
Lifecore Biomedical director Matthew E. Korenberg received a grant of 25,907 shares of common stock in the form of restricted stock units, with no cash paid per share. This award is compensation, not an open-market purchase, and increases his direct holdings to 69,967 shares.
The restricted stock units convert into common stock on a 1-for-1 basis and vest on the earlier of June 4, 2027 or the date of the Lifecore Biomedical annual stockholders meeting first held in calendar year 2027, provided that meeting occurs at least 50 weeks after June 4, 2026.
Director Humberto Calheiros Antunes of Lifecore Biomedical, Inc. reported receiving an award of 25,907 shares of common stock in the form of restricted stock units. The award has no cash exercise price and increases his direct holdings to 72,967 shares after the transaction.
The restricted stock units convert into common stock on a 1-for-1 basis and will vest on the earlier of June 4, 2027 or the date of Lifecore’s 2027 annual stockholders’ meeting, provided that meeting occurs at least 50 weeks after June 4, 2026.
Lifecore Biomedical director Paul Harold Johnson received an equity award of 25,907 restricted stock units that convert into common stock on a 1-for-1 basis. The award is recorded at a price of $0.00 per share as a grant/award acquisition and is held directly.
The units vest on the earlier of June 4, 2027 or the date of the company’s annual meeting of stockholders first held in calendar year 2027, provided that meeting occurs at least 50 weeks after June 4, 2026. Following this grant, Johnson holds 69,967 shares of common stock.
Lifecore Biomedical director Katrina Houde received an equity grant in the form of restricted stock units. She was awarded 25,907 shares of Common Stock on June 4, 2026 as a grant or award, at a stated price of $0.00 per share, indicating compensation rather than an open-market purchase.
After this grant, Houde directly holds 135,319 shares of Lifecore Biomedical common stock. According to the footnotes, the restricted stock units convert into common stock on a 1-for-1 basis and vest on the earlier of June 4, 2027 or the date of the company’s 2027 annual stockholder meeting, provided that meeting occurs at least 50 weeks after the grant date.
Lifecore Biomedical, Inc. reported results from its 2026 annual meeting of stockholders. Investors approved the 2026 Stock Incentive Plan, which will authorize 2,500,000 shares of common stock for equity awards, plus any shares returning from forfeited or expired awards under the existing 2019 plan. The new plan becomes effective on October 16, 2026, when the 2019 plan expires.
Stockholders also elected nine directors, including seven chosen by all voting stockholders and two elected solely by Series A preferred holders. They ratified KPMG LLP as independent auditor for 2026 and approved a non-binding advisory vote on executive compensation.
Lifecore Biomedical CEO Paul Josephs reported a tax-related share disposition. On the RSU vesting date, 40,413 shares of common stock were withheld by the company at $4.57 per share to cover withholding taxes. Josephs continues to hold 592,915 common shares directly after this transaction.